Исследование нового отечественного тромболитического препарата Фортелизин® у больных с острым инфарктом миокарда

Fortelyzin is a new thrombolytic, which represents a genemodified staphylokinase. The present clinical trial showed that Fortelyzin and Actilyse are comparative effective thrombolytics estimating reperfusion in patients with acute myocardial infarction according to TIMI grade. In the Actilyse patients group the fibrinogen level decreased more intensively then in Fortelyzin group. The safety was similar in both groups.